Albumin (Human) (albumin human) by Octapharma is glycoprotein. First approved in 2006.
Drug data last refreshed 8m ago · AI intelligence enriched 1w ago
Albumin (Human) is a human serum albumin (HSA) intravenous solution indicated for plasma volume expansion and osmotic regulation in critical care settings. It functions as a hyperoncotic colloid that restores intravascular oncotic pressure and carries hormones, enzymes, drugs, and toxins throughout circulation. The drug works by replacing lost albumin and leveraging its natural role as the primary osmotic regulator, accounting for 75% of normal intravascular oncotic pressure.
As a mature, LOE-approaching product with minimal Part D footprint, the Albumin Human brand team is likely small and focused on defensive positioning rather than growth, with limited expansion opportunities.
glycoprotein. It has the lowest molecular weight (66,241 Daltons) of all plasma proteins. Because of its three dimensional structure, solutions of albumin have a lower viscosity than solutions of other plasma proteins. This is important since work performed by the heart depends in part on the…
Human Serum Albumin
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on Albumin (Human) at Octapharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Joining the Albumin (Human) team offers stability and deep expertise in mature biologic commercialization, regulatory compliance, and healthcare supply chain management, but limited exposure to new product launches, clinical innovation, or rapid career escalation. This role suits professionals seeking subject-matter mastery in established-market biologics rather than high-growth, high-visibility product careers.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo